NO20082787L - Rensing og anvendelse av en faktor for a understotte leging av sar - Google Patents
Rensing og anvendelse av en faktor for a understotte leging av sarInfo
- Publication number
- NO20082787L NO20082787L NO20082787A NO20082787A NO20082787L NO 20082787 L NO20082787 L NO 20082787L NO 20082787 A NO20082787 A NO 20082787A NO 20082787 A NO20082787 A NO 20082787A NO 20082787 L NO20082787 L NO 20082787L
- Authority
- NO
- Norway
- Prior art keywords
- growth factor
- factor
- wounds
- purification
- application
- Prior art date
Links
- 206010052428 Wound Diseases 0.000 title 1
- 208000027418 Wounds and injury Diseases 0.000 title 1
- 230000035876 healing Effects 0.000 title 1
- 238000000746 purification Methods 0.000 title 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 2
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 abstract 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 abstract 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 abstract 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 abstract 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 abstract 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 abstract 2
- 229940116977 epidermal growth factor Drugs 0.000 abstract 2
- 229940126864 fibroblast growth factor Drugs 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 2
- 230000029663 wound healing Effects 0.000 abstract 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 abstract 1
- 108090000935 Antithrombin III Proteins 0.000 abstract 1
- 102100022977 Antithrombin-III Human genes 0.000 abstract 1
- 102100023915 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 abstract 1
- 229960005348 antithrombin iii Drugs 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000004140 cleaning Methods 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Det beskrives en fremgangsmåte for fremstilling av en sammensetning inneholdende en renset faktor for understøttelse av sårtilheling, valgt fra gruppen bestående av HGF (Hepatocyte Growth Factor), PDGF (Platelet derived growth factor), EGF (Epidermal growth factor), TGF-? (Transforming growth factor alfa), TGF-? (Transforming growth factor beta), IGF-I (Insulin like growth factor) og FGF (Fibroblast growth factor) fra kilder som blod, som inneholder faktoren for understøttelse av sårtilheling, hvor fremgangsmåten omfatter rensetrinn som foretas i nærvær av antitrombin III (AT-III).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06100819 | 2006-01-25 | ||
PCT/EP2007/050714 WO2007085626A1 (en) | 2006-01-25 | 2007-01-25 | Purification and use of a factor for supporting wound healing |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20082787L true NO20082787L (no) | 2008-10-13 |
Family
ID=36607451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20082787A NO20082787L (no) | 2006-01-25 | 2008-06-20 | Rensing og anvendelse av en faktor for a understotte leging av sar |
Country Status (14)
Country | Link |
---|---|
US (1) | US8962813B2 (no) |
EP (1) | EP1987054A1 (no) |
JP (1) | JP2009524622A (no) |
KR (1) | KR20080088610A (no) |
CN (1) | CN101374855A (no) |
AU (1) | AU2007209363B2 (no) |
BR (1) | BRPI0707268A2 (no) |
CA (1) | CA2640010A1 (no) |
IL (1) | IL192320A0 (no) |
NO (1) | NO20082787L (no) |
RU (1) | RU2520817C2 (no) |
UA (1) | UA94442C2 (no) |
WO (1) | WO2007085626A1 (no) |
ZA (1) | ZA200806382B (no) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7935364B2 (en) * | 2008-03-04 | 2011-05-03 | Wisconsin Alumni Research Foundation | Patterned gradient wound dressing and methods of using same to promote wound healing |
DE102009029194A1 (de) * | 2009-09-04 | 2011-04-07 | Kimberly-Clark Worldwide, Inc., Neenah | Abtrennung gefärbter Stoffe aus wasserhaltigen Flüssigkeiten |
WO2011028173A1 (en) * | 2009-09-05 | 2011-03-10 | Fariba Nayeri | Method of treatment of a patient suffering from an infection or injuries caused or complicated by infection |
AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
US8796430B2 (en) | 2010-05-26 | 2014-08-05 | Baxter International Inc. | Method to produce an immunoglobulin preparation with improved yield |
IL210162A0 (en) * | 2010-12-21 | 2011-03-31 | Omrix Biopharmaceuticals | Viral inactivated platelet extract, use and preparation thereof |
US9901597B2 (en) | 2011-02-04 | 2018-02-27 | Octapharma Ag | Method for inactivation/removal of coagulation factors by precipitation |
KR101965592B1 (ko) * | 2011-11-22 | 2019-08-13 | (주)아모레퍼시픽 | 성장 인자를 포함하는 피부 재생 촉진제 |
US9220646B2 (en) | 2012-03-30 | 2015-12-29 | Kimberly-Clark Worldwide, Inc. | Absorbent articles with improved stain decolorization |
US9237975B2 (en) | 2013-09-27 | 2016-01-19 | Kimberly-Clark Worldwide, Inc. | Absorbent article with side barriers and decolorizing agents |
US10239926B2 (en) | 2015-02-27 | 2019-03-26 | The University Of Vermont And State Agriculture College | Compositions and methods for vascular protection against reperfusion injury after myocardial ischemia |
US10722535B2 (en) | 2015-08-13 | 2020-07-28 | Kamada Ltd. | Compositions derived from Cohn fraction paste and use thereof |
CN105797205B (zh) * | 2016-04-20 | 2018-08-31 | 江苏迈健生物科技发展股份有限公司 | 干细胞培养上清凝胶及其制备方法 |
CN107216384A (zh) * | 2017-05-11 | 2017-09-29 | 深圳市卫光生物制品股份有限公司 | 一种人血浆转铁蛋白分离纯化的方法 |
US20210087224A1 (en) * | 2019-09-20 | 2021-03-25 | Plasma Technologies, Llc | Compositions and methods for generating modified cryo poor plasma |
WO2021054999A1 (en) * | 2019-09-20 | 2021-03-25 | Plasma Technologies, Llc | Therapeutic protein compositions and methods |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6045534A (ja) * | 1983-08-22 | 1985-03-12 | Otsuka Pharmaceut Co Ltd | 肝実質細胞増殖因子 |
JPS60243019A (ja) * | 1984-05-17 | 1985-12-03 | Mitsubishi Chem Ind Ltd | 肝細胞増殖因子 |
US4673733A (en) * | 1985-04-11 | 1987-06-16 | Sudhish Chandra | Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents |
US4839298A (en) * | 1986-02-14 | 1989-06-13 | Akzo N.V. | Virus inactivating diluents used in immunoassays |
JP2564486B2 (ja) * | 1986-07-14 | 1996-12-18 | 修治 橋本 | 肝細胞増殖因子 |
NZ232813A (en) * | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
GB9110202D0 (en) * | 1991-05-10 | 1991-07-03 | Erba Carlo Spa | Truncated forms of the hepatocyte growth factor(hgf)receptor |
US5348941A (en) * | 1992-04-01 | 1994-09-20 | Merck & Co., Inc. | Stabilizers for fibroblast growth factors |
AUPN858596A0 (en) * | 1996-03-08 | 1996-04-04 | Csl Limited | Filtration of plasma precipitates using cellulose filter aid |
SE0000178D0 (sv) * | 2000-01-21 | 2000-01-21 | Pharmacia & Upjohn Ab | Protein purification I |
US6451978B2 (en) * | 2000-01-21 | 2002-09-17 | Biovitrum Ab | Purification of antithrombin-III-α and β |
AU2006259408A1 (en) * | 2005-06-17 | 2006-12-28 | Genentech, Inc. | Use of VEGF for wound healing |
-
2007
- 2007-01-25 JP JP2008551784A patent/JP2009524622A/ja active Pending
- 2007-01-25 KR KR1020087018153A patent/KR20080088610A/ko not_active Application Discontinuation
- 2007-01-25 CN CNA2007800029120A patent/CN101374855A/zh active Pending
- 2007-01-25 EP EP07726226A patent/EP1987054A1/en not_active Withdrawn
- 2007-01-25 RU RU2008134479/10A patent/RU2520817C2/ru not_active IP Right Cessation
- 2007-01-25 US US12/162,107 patent/US8962813B2/en not_active Expired - Fee Related
- 2007-01-25 WO PCT/EP2007/050714 patent/WO2007085626A1/en active Application Filing
- 2007-01-25 AU AU2007209363A patent/AU2007209363B2/en not_active Ceased
- 2007-01-25 UA UAA200810618A patent/UA94442C2/ru unknown
- 2007-01-25 CA CA002640010A patent/CA2640010A1/en not_active Abandoned
- 2007-01-25 BR BRPI0707268-6A patent/BRPI0707268A2/pt not_active IP Right Cessation
-
2008
- 2008-06-19 IL IL192320A patent/IL192320A0/en unknown
- 2008-06-20 NO NO20082787A patent/NO20082787L/no not_active Application Discontinuation
- 2008-07-23 ZA ZA200806382A patent/ZA200806382B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US20100261651A9 (en) | 2010-10-14 |
WO2007085626A1 (en) | 2007-08-02 |
US20090221491A1 (en) | 2009-09-03 |
RU2008134479A (ru) | 2010-02-27 |
EP1987054A1 (en) | 2008-11-05 |
CA2640010A1 (en) | 2007-08-02 |
IL192320A0 (en) | 2008-12-29 |
CN101374855A (zh) | 2009-02-25 |
AU2007209363B2 (en) | 2013-08-22 |
US8962813B2 (en) | 2015-02-24 |
BRPI0707268A2 (pt) | 2011-04-26 |
KR20080088610A (ko) | 2008-10-02 |
ZA200806382B (en) | 2009-06-24 |
AU2007209363A1 (en) | 2007-08-02 |
RU2520817C2 (ru) | 2014-06-27 |
UA94442C2 (ru) | 2011-05-10 |
JP2009524622A (ja) | 2009-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20082787L (no) | Rensing og anvendelse av en faktor for a understotte leging av sar | |
AU2009315204A8 (en) | Additive for differentiation induction culture medium, and use thereof | |
SG178797A1 (en) | Oligosaccharide chain added glp-1 peptide | |
MX2010008094A (es) | Endoprotesis/endoprotesis cubierta para refuerzo de anormalidades vasculares y metodo asociado. | |
CL2007003627A1 (es) | Compuestos derivados de 3-h-pirazolopiridinas; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades de crecimiento vascular desregulado tal como leucemia mielogena aguda, retinopatia, artritis reumatoide, psorias | |
MY148096A (en) | 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments | |
BR122017015106B8 (pt) | estrutura de cristal de formula 1b e composição farmacêutica | |
MX2012003558A (es) | Procedimiento para la purificacion de eritropoyetina humana recombinante (epo), epo asi purificada y composiciones farmaceuticas que la comprenden. | |
NZ593111A (en) | Antibacterial compounds | |
SG169366A1 (en) | Pharmaceutical composition of microspheres for preventing diabetic foot amputation | |
BR112012027815A2 (pt) | controle da atividade bacteriana, tal como em esgotos e sistemas de tratamento de águas residuais | |
MY151973A (en) | Cyclic depsipeptides | |
ATE443722T1 (de) | Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung | |
DE602005020185D1 (de) | Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4henprodukte für dieses verfahren | |
DE602005001688D1 (de) | Aufbereitung von Aldesleukin zur pharmazeutischen Verwendung | |
AU2006331223A8 (en) | Use of a topical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention | |
MX343745B (es) | Nuevos acidos fosfinicos y sus derivados y metodos para su preparacion. | |
NO20091788L (no) | Antibakterielle og antivirale peptider fra Actinomadura namibiensis | |
UA104281C2 (ru) | Противоопухолевые аналоги пептидов, способ их получения и фармацевтическая композиция на них основе | |
DE60219403D1 (de) | Verfahren zur Herstellung einer desinfizierenden Zusammensetzung, Desinfektionsverfahren für medizinische Vorrichtungen | |
AU2003226276A1 (en) | Oxygen enriched implant for orthopedic wounds | |
GB2483195A (en) | Novel uses | |
FI20045307A (fi) | Kipsilevyn pinnoite ja kipsilevy | |
ATE527997T1 (de) | Verwendung von aminapthon zur herstellung eines medikaments zur behandlung von arteriopathien | |
ATE438648T1 (de) | Verfahren zur herstellung von 10alpha-ä4'-(s-s- dioxothothiomorpholin-1'-yl)ü-10-deoxo-10- dihydroartemisinin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |